- Previous Close
330.55 - Open
330.60 - Bid 341.05 x --
- Ask 344.95 x --
- Day's Range
325.65 - 344.95 - 52 Week Range
302.05 - 414.00 - Volume
3,969 - Avg. Volume
3,742 - Market Cap (intraday)
1.053B - Beta (5Y Monthly) -0.03
- PE Ratio (TTM)
11.83 - EPS (TTM)
28.82 - Earnings Date May 30, 2025
- Forward Dividend & Yield 1.00 (0.30%)
- Ex-Dividend Date Sep 19, 2024
- 1y Target Est
--
Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodic acid, iodine, iodine monochloride, iodoquinol, lithium iodide, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate, potassium iodide, potassium metaper iodate, povidone iodine, selenium dioxide, sodium iodate, sodium iodide, sodium metaper iodate, sodium selenite, and tri methyl sulphoxonium iodide. The company serves agrochemical, animal feed, chemical, cosmetics, food, LCD screen, contrast media, pharmaceutical, screen printing, nylon textile, and tire cord manufacturing industries. It also exports its products to the United States, Europe, Africa, Asia, the Middle East, and internationally. Samrat Pharmachem Limited was incorporated in 1992 and is based in Mumbai, India.
www.samratpharmachem.comRecent News: SAMRATPH.BO
View MorePerformance Overview: SAMRATPH.BO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAMRATPH.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAMRATPH.BO
View MoreValuation Measures
Market Cap
1.05B
Enterprise Value
1.07B
Trailing P/E
11.82
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
1.52
Enterprise Value/Revenue
0.36
Enterprise Value/EBITDA
8.43
Financial Highlights
Profitability and Income Statement
Profit Margin
2.99%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
2.97B
Net Income Avi to Common (ttm)
89.07M
Diluted EPS (ttm)
28.82
Balance Sheet and Cash Flow
Total Cash (mrq)
71.92M
Total Debt/Equity (mrq)
13.16%
Levered Free Cash Flow (ttm)
--